Which pathological findings indicate corticobasal degeneration (CBD)?

Updated: Sep 24, 2018
  • Author: Stephen M Bloomfield, MD; Chief Editor: Selim R Benbadis, MD  more...
  • Print


CBD is now classified as a 4-repeat tauopathy. [37] Neuropathologic diagnostic criteria include tau-immunoreactive lesions in neurons, glia, and cell processes. The minimal pathologic features for diagnosis are cortical and striatal tau-positive neuronal and glial lesions, especially astrocytic plaques and threadlike structures in both white matter and gray matter combined with neuronal loss both in focal cortical lesions and substantia nigra. These criteria help distinguish the disease from other tauopathies, with the exception of frontotemporal dementia and parkinsonism related to chromosome 17 mutations (FTDP-17). Of note, patients meeting these pathologic criteria may not have had the classic clinical presentation of CBD.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!